Role of Pleiotropic Properties of Peroxisome Proliferator‐Activated Receptors in the Heart: Focus on the Nonmetabolic Effects in Cardiac Protection. Issue 1 (February 2016)

• Record Type: Journal Article
• Authors: Barlaka, Eleftheria; Galatou, Eleftheria; Mellidis, Kyriakos; Ravingerova, Tanya; Lazou, Antigone
• Is Part Of: Cardiovascular therapeutics. Volume 34:Issue 1(2016:Feb.)
• Page Start: 37
• Page End: 48
• Publication Date: 2016-02
• Subjects: Cardiac disorders -- Inflammation -- Nonmetabolic -- Nuclear receptors -- Oxidative stress; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals; Cardiovascular Agents -- Periodicals; Cardiovascular Diseases -- drug therapy -- Periodicals; Agents cardiovasculaires -- Périodiques; Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques; 616.1005
• DOI: 10.1111/1755-5922.12166
• Languages: English
• ISSNs: 1755-5914

Abstract

Summary: Peroxisome proliferator‐activated receptors, PPARα, PPARβ/δ, and PPARγ, are a group of nuclear receptors that function as transcriptional regulators of lipid metabolism, energy homeostasis, and inflammation. Given the role of metabolism imbalance under pathological states of the heart, PPARs have emerged as important therapeutic targets, and accumulating evidence highlights their protective role in the improvement of cardiac function under diverse pathological settings. Although the role of PPARs in the regulation of cardiac substrate utilization preference and energy homeostasis is well documented, their effects related to the regulation of cellular inflammatory and redox responses in the heart are less studied. In this review, we provide an overview on recent progress with respect to understanding the role of the nonmetabolic effects of PPARs in cardiac dysfunction, namely during ischemia/reperfusion injury, hypertrophy, and cardiac failure, and highlight the mechanisms underlying the protective effects against inflammation, oxidative stress, and cell death. The role of receptor‐independent, nongenomic effects of PPAR agonists is also discussed.